Comparative analysis of sperm count, hormonal profile and testicular volume before and after intra-testicular PRP therapy in non-obstructive azoospermia
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20254267Keywords:
Male infertility, Nonobstructive azoospermia, Platelet-rich plasmaAbstract
Background: Non-obstructive azoospermia (NOA) is a major cause of male infertility, with limited treatment options. Platelet-rich plasma (PRP), which is rich in growth factors, has been proposed as a regenerative therapy. This study conducted a comparative analysis of sperm count, hormonal profiles and testicular volume before and after intratesticular autologous PRP therapy in men with NOA.
Methods: This self-controlled clinical trial was conducted at the Department of Reproductive Endocrinology and Infertility, BSMMU, Dhaka, from January 2022 to July 2023. Thirty men with NOA underwent intratesticular injection of autologous PRP (2–3 ml per testis). Baseline and follow-up assessments at 1 and 3 months included semen analysis, clinical and ultrasound measurements of serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone and testicular volume. Data were analyzed using SPSS v26.
Results: No spermatozoa were detected in semen samples at baseline, 1 month or 3 months post-treatment. Hormonal profiles showed mild fluctuations without significance (FSH: 33.1 to 24.3 mIU/ml, p=0.061, LH: 9.5 to 9.6 mIU/ml, p=0.562, testosterone: 392.0 to 435.1 ng/dl, p=0.062). Mean testicular volume increased from 9.5±2.3 ml to 11.2±2.4 ml (p=0.004) using the Prader orchidometer and from 10.0±2.4 ml to 11.3±2.4 ml (p=0.002) using ultrasound. Side effects included transient pain (20.0%) and hematoma (20.0%), with no infections reported.
Conclusions: Intratesticular PRP increased testicular volume but did not restore spermatogenesis or alter hormones significantly in NOA patients. Although safe and biologically plausible, its clinical utility requires validation through larger, long-term trials.
References
Jarvi K, Lo K, Grober E, Mak V, Fischer A, Grantmyre J, et al. The workup and management of azoospermic males. Canadian Urolog Assoc J. 2015;9(8):229.
Jungwirth A, Giwercman A, Tournaye H, Diemer T, Kopa Z, Dohle G, et al. EAU Working Group on Male Infertility. European Association of Urology guidelines on Male Infertility. European Urol. 2012;62(2):324-32.
Tharakan T, Luo R, Jayasena CN, Minhas S. Non-obstructive azoospermia: current and future perspectives. Faculty Rev. 2021;26:10.
Esteves SC. Clinical management of infertile men with nonobstructive azoospermia. Asian J Androl. 2015;17(3):459-70.
Iwatsuki S, Sasaki S, Taguchi K, Hamakawa T, Mizuno K, Okada A, et al. Effect of obesity on sperm retrieval outcome and reproductive hormone levels in Japanese azoospermic men with and without Klinefelter syndrome. Andrology. 2017;5(1):82-6.
Hauser R, Yogev L, Paz G, Yavetz H, Azem F, Lessing JB, et al. Comparison of efficacy of two techniques for testicular sperm retrieval in nonobstructive azoospermia: multifocal testicular sperm extraction versus multifocal testicular sperm aspiration. J Androl. 2006;27(1):28-33.
Vij SC, Sabanegh JE, Agarwal A. Biological therapy for non-obstructive azoospermia. Expert Opin Biol Ther. 2018;18(1):19-23.
Colombo GV, Fanton V, Sosa D, Criado Scholz E, Lotti J, Aragona SE, et al. Use of platelet rich plasma in human infertility. J Biol Regul Homeost Agents. 2017;1;31(2):179-82.
Battinelli EM, Markens BA, Italiano JE. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood J American Soc Hematol. 2011;118(5):1359-69.
Pietrzak WS, Eppley BL. Platelet rich plasma: biology and new technology. J Craniofac Surg. 2005;16(6):1043-54.
Hendriks S, Dancet EA, Meissner A, Van der Veen F, Mochtar MH, Repping S. Perspectives of infertile men on future stem cell treatments for nonobstructive azoospermia. Reprod Biomed. 2014;28(5):650-7.
Valerıya Z, Olena K, Olena K. Platelet-rich plasma induces morphofunctional restoration of mice testes following doxorubomycine hydrochloride exposure. J Exp Clin Med. 2014;31(3):183-7.
Al-Nasser R, Khrait Z, Jamali S. The Effectiveness of autologous platelet-rich plasma (prp) in the therapy of infertile men with non-abstractive azoospermia. J Reprod Med Gynecol Obstet. 2018;3(11):975.
Angellee J, Ginting CN, Chiuman L, Halim B. Role of platelet-rich plasma to sperm quality in male partners undergoing infertility treatment. In 2021 IEEE International Conference on Health. Instrument Meas Natural Sci. 2021;3:1-5.
Belloc S, Cohen-Bacrie M, Amar E, Izard V, Benkhalifa M, Dalléac A, et al. High body mass index has a deleterious effect on semen parameters except morphology: results from a large cohort study. Fertil Ster. 2014;102(5):1268-73.
Kutluhan MA, Özsoy E, Şahin A, Ürkmez A, Topaktaş R, Toprak T, et al. Effects of platelet‐rich plasma on spermatogenesis and hormone production in an experimental testicular torsion model. Andrology. 2021;9(1):407-13.
Dehghani F, Sotoude N, Bordbar H, Panjeshahin MR, Karbalay-Doust S. The use of platelet-rich plasma (PRP) to improve structural impairment of rat testis induced by busulfan. Platelets. 2019;30(4):513-20.
Somova O, Ivanova H, Sotnyk N, Kovalenko K, Feskova I. Effectiveness of platelet-rich plasma treatment in men with severe oligoasthenoteratozoospermia. Hum Reprod. 2021;36:81–2.
Downloads
Published
How to Cite
Issue
Section
